US Northwestern trial shows drug doubles one‑year survival in pancreatic cancer

A Northwestern University trial in the U.S. found an experimental drug roughly doubled one‑year survival for advanced pancreatic cancer patients when added to chemotherapy.

Pancreatic cancer carries a five‑year survival rate below ten percent, making any improvement in outcomes a potential breakthrough for patients and clinicians alike. Extending life by even a few months can increase eligibility for additional treatments and improve quality of life.

The randomized Phase 2 study enrolled adults with metastatic disease and compared standard chemotherapy alone with chemotherapy plus the investigational agent. Researchers said the trial was a Phase 2 effort, a detail reported by Hoodline^[2].

Patients receiving the experimental drug were about twice as likely to be alive at one year compared with chemotherapy alone, a result that Live Science called a two‑fold increase^[1]. The investigators said the drug doubled the proportion of patients who survived the first year of treatment.

Media reports differ on the drug’s name. Hoodline and several other outlets identify it as elraglusib, while Gizmodo refers to the compound as daraxonrasib and labels the study a Phase III trial^[3]. The majority of sources, including the peer‑reviewed summary cited by Live Science, use the elraglusib designation and describe the work as a Phase 2 trial, suggesting the latter is the more widely accepted characterization.

The agent is designed to make pancreatic tumors more vulnerable to chemotherapy and to the body’s immune response, thereby extending survival, according to the study’s authors^[4]. By inhibiting a pathway that tumors use to evade immune detection, the drug may amplify the effects of standard treatment.

"Remarkable," a medical oncologist said of the findings, underscoring the rarity of such gains in a disease that has long resisted therapeutic advances.

The next step will be a larger, possibly multinational Phase 3 trial to confirm safety and efficacy across a broader patient population. Regulators will review the data before considering any emergency use authorization, but the early results have already sparked optimism among oncologists seeking new options for a notoriously lethal cancer.

**What this means** – If the survival benefit holds up in later‑stage testing, the drug could become the first addition to standard chemotherapy that meaningfully extends life for advanced pancreatic cancer patients, potentially reshaping treatment protocols and offering hope to a community that has seen few breakthroughs.